Financial Performance - The company's operating revenue for 2022 was ¥15,933,984,403.41, representing a 6.82% increase compared to ¥14,797,989,091.20 in 2021[11]. - The net profit attributable to shareholders for 2022 was ¥3,620,271,034.96, a decrease of 16.89% from ¥4,324,150,263.31 in 2021[11]. - The net cash flow from operating activities decreased by 25.29% to ¥4,361,481,083.61 in 2022, down from ¥5,837,878,051.57 in 2021[11]. - The total assets at the end of 2022 were ¥38,267,625,155.83, an increase of 10.21% from ¥34,692,165,111.88 at the end of 2021[11]. - The net assets attributable to shareholders increased by 7.98% to ¥23,574,859,468.61 at the end of 2022, compared to ¥21,799,977,645.94 at the end of 2021[11]. - The basic earnings per share for 2022 was ¥1.17, down 17.02% from ¥1.68 in 2021[11]. - The company reported a total of ¥33,397,934.74 in non-recurring gains and losses for 2022, significantly lower than ¥176,216,898.47 in 2021[16]. - Total revenue for 2022 reached ¥15,933,984,403.41, representing a year-over-year increase of 6.82% from ¥14,917,101,500.91 in 2021[42]. - The pharmaceutical and chemical sector contributed ¥14,672,567,397.29, accounting for 92.08% of total revenue, with a growth of 5.52% compared to the previous year[42]. - Nutritional products generated ¥10,951,828,026.72, which is 68.73% of total revenue, but saw a slight decline of 1.94% year-over-year[42]. Dividend Distribution - The company plans to distribute a cash dividend of 5 CNY per 10 shares (including tax) to all shareholders, based on a total share capital of 3,073,421,680 shares after excluding repurchased shares[2]. - The cash dividend distribution for 2021 was 7 RMB per 10 shares, totaling 1,793,794,088.80 RMB[189]. - For the current reporting period, the cash dividend per 10 shares is set at 5 RMB, with a total cash dividend amounting to 1,716,395,391.90 RMB, representing 100% of the distributable profit[135]. - The total number of shares after the capital increase is 3,090,907,356, with 3,073,421,680 shares being the basis for the dividend distribution[135]. Business Stability and Governance - The company has not reported any changes in its main business since its listing, indicating stability in its operations[9]. - The company has not experienced any changes in its controlling shareholders, indicating stability in ownership[9]. - The company emphasizes the importance of accurate financial reporting, with the management team ensuring the authenticity and completeness of the annual report[1]. - The company is committed to adhering to regulatory requirements as outlined by the China Securities Regulatory Commission[6]. - The company has maintained effective internal controls as of December 31, 2022, according to the internal control audit report[145]. - The company has not reported any significant internal control deficiencies during the reporting period[142]. - The company has implemented strict labor management policies, ensuring all employees are under formal contracts and receive salaries directly from the company[104]. - The company respects and protects the legitimate rights and interests of stakeholders, ensuring a balance of interests among shareholders, employees, and society[101]. Market Position and Strategy - The company is recognized as one of the world's top four vitamin producers and a leading enterprise in fine chemicals in China[24]. - The company is actively developing its nutrition business, optimizing process routes, and enhancing product competitiveness through new product series and high value-added layouts[25]. - The company aims to enhance operational efficiency and reduce energy consumption per unit of output through innovative production management and optimization of production processes[28]. - The company is focused on enhancing investor relations, ensuring that all shareholders, especially minority shareholders, have equal rights and access to information[100]. - The company is committed to sustainable high-quality development by leveraging its four modern production bases in Zhejiang and Shandong provinces[85]. - The company aims to diversify its flavor and fragrance product structure, moving beyond its current focus on specific series to introduce new integrated and differentiated products[86]. - The operational strategy for 2023 emphasizes market expansion, cost reduction through innovation, and risk management, with a focus on stable production and project execution[87]. Research and Development - The company maintains a research and development investment exceeding 5% of its revenue annually, focusing on key technologies for industry transformation[35]. - R&D investment amounted to ¥858,945,406.13 in 2022, a 9.75% increase from ¥782,661,708.54 in 2021, representing 5.39% of operating revenue[56]. - The company is conducting research on high-safety nutrient products, with three products already in large-scale application, supporting its market presence in Europe[53]. - The company is working on the synthesis and industrialization of adiponitrile, aiming to break foreign monopolies and promote domestic industry development[53]. - The company has made progress in developing a new process for vitamin A and AD3 formulations, focusing on improving product stability and quality[53]. Environmental Management - The company has received multiple environmental approvals for various projects throughout 2022, including the taurine project and methionine phase II project[148][149]. - The company is classified as a key pollutant discharge unit by environmental protection authorities[147]. - The company has implemented various environmental management measures in line with national regulations[147]. - The company has invested CNY 528.35 million in environmental protection measures during the reporting period[161]. - The company has established a standardized hazardous waste storage facility and incineration system, handling most hazardous waste internally[156]. Investor Relations - The company conducted an investor relations activity on May 10, 2022, discussing its operational status and responding to investor inquiries[96]. - The investor relations activities included participation from multiple prominent investment firms, indicating strong interest in the company's performance[96]. - The company emphasized its commitment to transparency and regular communication with investors through detailed reports available on its official website[96]. - The company aims to maintain a robust dialogue with investors to ensure alignment on business objectives and performance expectations[96]. Employee and Talent Development - R&D personnel increased to 2,629 in 2022, up 11.02% from 2,368 in 2021, with a proportion of 22.81% of total employees[55]. - The company emphasizes talent development through various training programs aimed at enhancing management and technical skills[131]. - The company has a competitive compensation policy that includes basic salary, performance pay, and welfare allowances, ensuring full compliance with social insurance regulations[130]. - The company is focused on building a high-performance talent pool by optimizing its organizational structure and enhancing recruitment channels[89]. Risk Management - The management has outlined potential risks and corresponding mitigation strategies in the future development outlook section of the report[1]. - The company is addressing raw material price volatility risks by enhancing market analysis and establishing strategic partnerships with suppliers[92]. - The company recognizes the risks posed by macroeconomic uncertainties and aims to diversify its innovation chain and customer base to ensure steady growth[91].

Financial Performance - The company's revenue for Q1 2023 was ¥3,612,227,625.99, a decrease of 16.15% compared to ¥4,307,991,748.95 in the same period last year[4]. - Net profit attributable to shareholders was ¥643,158,260.22, down 46.55% from ¥1,203,327,294.72 year-on-year[4]. - The basic and diluted earnings per share were both ¥0.21, representing a decline of 46.15% compared to ¥0.47 in the previous year[5]. - Total operating revenue for Q1 2023 was CNY 3,612,227,625.99, a decrease of 16.1% compared to CNY 4,307,991,748.95 in the same period last year[28]. - Net profit for Q1 2023 was CNY 646,920,492.73, a decline of 46.5% from CNY 1,207,852,620.67 in Q1 2022[30]. - The total comprehensive income attributable to the parent company was ¥637,863,976.49, down from ¥1,201,411,469.57 in Q1 2022, reflecting a decline of 47.1%[31]. Assets and Liabilities - The total assets at the end of the reporting period increased by 3.27% to ¥39,517,620,455.25 from ¥38,267,625,155.83 at the end of the previous year[5]. - The total liabilities increased to CNY 15,206,835,983.36, compared to CNY 14,605,475,920.37 at the beginning of the year, reflecting a growth of 4.1%[26]. - The company's total equity attributable to shareholders increased by 2.73% to ¥24,218,478,672.98 from ¥23,574,859,468.61 at the end of the previous year[5]. - The company's total equity attributable to shareholders increased to CNY 24,218,478,672.98, up from CNY 23,574,859,468.61 at the beginning of the year, reflecting a growth of 2.7%[27]. Cash Flow - The company’s cash flow from operating activities was ¥390,927,539.55, a decrease of 7.46% from ¥422,441,679.66 in the previous year[4]. - Cash inflow from operating activities totaled ¥3,975,891,634.38, slightly up from ¥3,918,104,101.36 in Q1 2022[33]. - The net cash flow from operating activities was ¥390,927,539.55, down 7.4% from ¥422,441,679.66 in the same period last year[34]. - Cash outflow from investing activities was ¥1,246,861,810.80, a decrease from ¥2,249,949,764.68 in Q1 2022, indicating a reduction of 44.4%[34]. - The net cash flow from investing activities was -¥842,833,510.01, an improvement from -¥1,167,749,765.14 in the previous year[34]. - Cash inflow from financing activities was ¥1,625,467,898.96, slightly down from ¥1,637,682,567.39 in Q1 2022[35]. - The net cash flow from financing activities was ¥968,011,828.56, a minor decrease from ¥972,224,884.10 in the same period last year[35]. Investments and Other Income - Long-term equity investments increased by 31.53% due to investments in joint ventures during the reporting period[9]. - The company reported a 41.45% increase in other income for Q1, primarily due to an increase in government subsidies[12]. - Long-term equity investments rose to CNY 568,890,752.94, an increase of 31.6% from CNY 432,503,568.48 at the start of the year[26]. Shareholder Information - The total number of common shareholders at the end of the reporting period is 119,034[19]. - The largest shareholder, New Hecheng Holdings Group Co., Ltd., holds 49.22% of shares, totaling 1,521,362,525 shares[19]. - The company raised a total of RMB 490 million from a non-public offering of 17.5 million shares at RMB 28.00 per share[21]. Inventory and Receivables - The total inventory as of March 31, 2023, is RMB 4,518,455,983.83, up from RMB 4,144,557,702.39 at the beginning of the year[24]. - The company’s accounts receivable stands at RMB 2,483,287,515.02, slightly up from RMB 2,476,269,041.23 at the beginning of the year[24]. - The company’s trading financial assets decreased to RMB 340,000,000.00 from RMB 720,314,576.43 at the beginning of the year[24]. Research and Development - Research and development expenses for Q1 2023 were CNY 190,075,834.44, a decrease of 16.6% from CNY 227,817,615.86 in Q1 2022[28].

证券代码：002001 证券简称：新和成 公告编号：2023-020 浙江新和成股份有限公司 关于举行 2022 年度网上业绩说明会的通知 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 浙江新和成股份有限公司（以下简称"公司"）于 2023 年 4 月 21 日披露 《2022 年年度报告》及《2022 年年度报告摘要》，为便于广大投资者进一步了 解公司 2022 年年度报告及经营情况，公司将于 2023 年 4 月 26 日（星期三）下 午 15:00-17:00 在全景网举行 2022 年度业绩说明会，本次年度业绩说明会将采用 网络远程的方式举行，投资者可登陆全景网"投资者关系互动平台" （https://ir.p5w.net/）参与本次年度业绩说明会。 出席本次说明会的人员有：董事长胡柏藩先生、副董事长兼总裁胡柏剡先生、 董事会秘书兼财务总监石观群先生、独立董事金赞芳女士。 为充分尊重投资者、提升交流的针对性，现就公司 2022 年度业绩说明会提 前向投资者公开征集问题，广泛听取投资者的意见和建议。投资者可于 2023 年 4 月 25 日（星期二）下 ...